Sawai Group Holdings Co., Ltd. (TYO:4887)

Japan · Delayed Price · Currency is JPY

1,659.50

-3.00 (-0.18%)

Jul 24, 2026, 3:30 PM JST

-15.05% (1Y)

Market Cap	191.65B -15.0%
Revenue (ttm)	201.68B +6.7%
Net Income	10.44B -12.8%
EPS	90.10 -6.4%
Shares Out	115.49M
PE Ratio	16.66
Forward PE	10.25
Dividend	56.00 (3.37%)
Ex-Dividend Date	Sep 29, 2026

Volume	293,000
Open	1,655.00
Previous Close	1,662.50
Day's Range	1,645.00 - 1,670.50
52-Week Range	1,591.00 - 2,447.00
Beta	0.03
Analysts	Buy
Price Target	2,294.44 (+38.26%)
Earnings Date	Aug 10, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1929

Employees 3,630

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4887

Full Company Profile

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 4887 stock is "Buy." The 12-month stock price target is ¥2,294, which is an increase of 38.26% from the latest price.

Price Target

¥2,294

(38.26% upside)

Analyst Consensus: Buy

Stock Forecasts